{"disease":{"id":"ros1-rearrangement","name":"ros1 rearrangement"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05055232","title":"A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Xuanzhu Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04292119","title":"Lorlatinib Combinations in Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03718117","title":"Descriptive Observational Study ALK-2016-CPHG","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06694129","title":"Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Center, China","has_results":false},{"nct_id":"NCT02321501","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04005144","title":"Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of California, San Francisco","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}